Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

ASEP Medical Holdings Inc. (JJ8.F)

Compare
0.0418
+0.0004
+(0.97%)
As of 9:59:02 AM GMT+2. Market Open.
Loading Chart for JJ8.F
  • Previous Close 0.0414
  • Open 0.0418
  • Bid 0.0418 x --
  • Ask 0.0472 x --
  • Day's Range 0.0418 - 0.0418
  • 52 Week Range 0.0254 - 0.1215
  • Volume 35,000
  • Avg. Volume 7,684
  • Market Cap (intraday) 3.502M
  • Beta (5Y Monthly) -1.94
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0400
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ASEP Medical Holdings Inc., together with its subsidiaries, focuses on developing diagnostic and therapeutic solutions for the treatment of sepsis. It offers peptide technology for therapeutic applications, including bacterial biofilm infections, anti-inflammatories, anti-infective immune-modulators, and vaccine adjuvants; diagnostic kits for predicting the onset of severe sepsis and organ failure; and coatings for medical devices. The company was formerly known as Trenchant Life Sciences Investment Corp. and changed its name to ASEP Medical Holdings Inc. in November 2021. ASEP Medical Holdings Inc. was incorporated in 2021 and is headquartered in Victoria, Canada.

asepmedical.com

6

Full Time Employees

December 31

Fiscal Year Ends

Recent News: JJ8.F

View More

Performance Overview: JJ8.F

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

JJ8.F
48.23%
S&P/TSX Composite index (^GSPTSE)
1.16%

1-Year Return

JJ8.F
60.19%
S&P/TSX Composite index (^GSPTSE)
10.36%

3-Year Return

JJ8.F
72.86%
S&P/TSX Composite index (^GSPTSE)
10.19%

5-Year Return

JJ8.F
72.86%
S&P/TSX Composite index (^GSPTSE)
88.09%

Compare To: JJ8.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: JJ8.F

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    3.47M

  • Enterprise Value

    3.48M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    19.34

  • Price/Book (mrq)

    0.47

  • Enterprise Value/Revenue

    22.09

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -11.39%

  • Return on Equity (ttm)

    -25.59%

  • Revenue (ttm)

    243.92k

  • Net Income Avi to Common (ttm)

    -4.64M

  • Diluted EPS (ttm)

    -0.0400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    52.69k

  • Total Debt/Equity (mrq)

    1.47%

  • Levered Free Cash Flow (ttm)

    795.94k

Research Analysis: JJ8.F

View More

Company Insights: JJ8.F

Research Reports: JJ8.F

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.